NASDAQ:SRNE
Delisted
Sorrento Therapeutics Stock News
$0.307
+0 (+0%)
At Close: Feb 23, 2023
Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product
04:45pm, Thursday, 01'st Sep 2022 Zacks Investment Research
Sorrento Therapeutics' (SRNE) subsidiary Scilex receives Fast Track designation for its lower back pain (LBP) candidate, SP-103. Stock Up.
Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product
01:53pm, Thursday, 01'st Sep 2022
Sorrento Therapeutics' (SRNE) subsidiary Scilex receives Fast Track designation for its lower back pain (LBP) candidate, SP-103. Stock Up.
Why Sorrento Therapeutics Stock Is Marching Higher Today
04:01pm, Wednesday, 31'st Aug 2022 The Motley Fool
An FDA fast track designation for a high-value product candidate is powering the biotech's shares higher today.
Why Sorrento Therapeutics Stock Is Marching Higher Today
12:01pm, Wednesday, 31'st Aug 2022
An FDA fast track designation for a high-value product candidate is powering the biotech's shares higher today.
Sorrento Therapeutics (SRNE) Pops on FDA Fast Track Designation
11:20am, Wednesday, 31'st Aug 2022
Source: Bukhta Yurii / Shutterstock.com Sorrento Therapeutics (NASDAQ: SRNE ) stock is getting a boost on Wednesday after the FDA granted it fast-track designation for SP-103. SP-103 is Sorrento Thera
Why Cepton Is Trading Higher By 19%; Here Are 28 Stocks Moving Premarket
11:14am, Wednesday, 31'st Aug 2022 Benzinga
Gainers
Software Acquisition Group Inc. III (NASDAQ: NOGN) shares rose 80.1% to $6.04 in pre-market trading after dropping over 65% on Tuesday.
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares rose 3
Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain (LBP)
03:21am, Wednesday, 31'st Aug 2022 GlobeNewswire Inc.
PALO ALTO, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for
Positive Abivertinib Trial Results Push Sorrento Therapeutics (SRNE) 6.2% Higher
09:12pm, Wednesday, 24'th Aug 2022
Biopharmaceutical outfit Sorrento Therapeutics (US:SRNE) rallied +6.2% on Tuesday and extended gains by a further +2.1% in post market trading after the company released positive trial results cnx.cmd
Sorrento (SRNE) Up on Positive Result From Lung Cancer Study
04:24pm, Wednesday, 24'th Aug 2022 Zacks Investment Research
Sorrento Therapeutics' (SRNE) stock rises after it announced positive results from its late-stage lung cancer study evaluating abivertinib.
2 Penny Stocks That Could Make You Filthy Rich
01:45pm, Wednesday, 24'th Aug 2022 The Motley Fool
These two penny stocks could generate life-changing gains for early shareholders.
Sorrento (SRNE) Up on Positive Result From Lung Cancer Study
01:32pm, Wednesday, 24'th Aug 2022
Sorrento Therapeutics' (SRNE) stock rises after it announced positive results from its late-stage lung cancer study evaluating abivertinib.
2 Penny Stocks That Could Make You Filthy Rich
09:45am, Wednesday, 24'th Aug 2022
These two penny stocks could generate life-changing gains for early shareholders.
Why Sorrento Therapeutics Stock Is Popping Today
07:08pm, Tuesday, 23'rd Aug 2022 The Motley Fool
A positive clinical readout in lung cancer is fueling the biotech's rally today.
Why Sorrento Therapeutics Stock Is Popping Today
03:08pm, Tuesday, 23'rd Aug 2022
A positive clinical readout in lung cancer is fueling the biotech's rally today.
Sorrento Therapeutics Announces China National Medical Products Administration (NMPA) IND Clearance of STI-1558, An Oral Mpro Inhibitor for Phase I Trial In COVID-19 Patients
01:00pm, Friday, 19'th Aug 2022 GlobeNewswire Inc.
SAN DIEGO, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the NMPA clearance of a Phase I study of its oral main viral protease (Mpro) inh
